<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22917" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>HIV Antiretroviral Therapy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kemnic</surname>
            <given-names>Tyler R.</given-names>
          </name>
          <aff>Michigan State University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gulick</surname>
            <given-names>Peter G.</given-names>
          </name>
          <aff>Michigan State University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tyler Kemnic declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Peter Gulick declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22917.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">A typical initial HIV regimen includes 3 HIV medications from a minimum of 2 drug classes. Although this treatment is not curative, it can provide longer lives for patients and reduce HIV transmission. This reduction of transmission has become a popular use of antiretroviral therapy for HIV-positive individuals with an HIV-negative partner. The successes of antiretroviral therapy have reduced HIV to a chronic condition in many parts of the world as progression to AIDS has become rare. Studies have found that the 3-drug regimen has led to a 60% to 80% decline in rates of AIDs, hospitalization, and death. By 2030, the CDC plans to implement a 90-90-90 plan (90% HIV diagnosed, 90% on therapy, and 90% suppressed). This activity describes the indications, contraindications, and use of HIV antiretroviral therapy and highlights the role of the interprofessional team in promoting their safety.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of HIV medications approved by the Food and Drug administration.</p></list-item><list-item><p>Identify the adverse effects of HIV&#x000a0;antiretroviral&#x000a0;therapy medications.</p></list-item><list-item><p>Determine&#x000a0;the appropriate monitoring steps of&#x000a0;antiretroviral&#x000a0;therapy medications.</p></list-item><list-item><p>Communicate&#x000a0;the importance of improving care coordination amongst the interprofessional team to enhance care delivery for patients with HIV and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22917&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22917">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22917.s2" sec-type="Indications">
        <title>Indications</title>
        <p>The first therapy to work against HIV was the nucleoside reverse transcriptase inhibitor zidovudine. The Food and Drug Administration (FDA) approved this in 1987. By 1996, research showed the advantages of combining medicines to treat HIV. Using HIV medicines for treatment is called antiretroviral therapy (ART). This form of therapy is recommended for all patients with HIV by the Department of Health and Human Services (DHHS) and the World Health Organization (WHO). This daily treatment of multiple HIV medications is an HIV regimen. A typical initial HIV regimen includes&#x000a0;3 HIV medications from a minimum of two drug classes. Although this treatment is not curative, it can provide longer lives for patients and reduce HIV transmission.</p>
        <p>This reduction of transmission has become a widespread use of antiretroviral therapy for HIV-positive individuals who are with an HIV-negative partner. The successes of antiretroviral therapy have reduced HIV to a chronic condition in many parts of the world as progression to AIDS has become rare. Studies have found that 3-drug therapy has led to a 60% to 80% decline in the rates of AIDs, hospitalization, and death. By 2030, the CDC plans to implement a 90-90-90 plan (90% HIV diagnosed, 90% on therapy, and 90% suppressed).&#x000a0;</p>
        <p>The goal of HIV medicines is to prevent HIV from multiplying. There are&#x000a0;6 classes of drugs used in antiretroviral therapy. These drugs generally fall into classes according to the phase of the HIV life cycle they inhibit. More common combinations include 2 nucleoside reverse transcriptase inhibitors (NRTIs) and 1 non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI), or an integrase inhibitor (II). The drugs are listed below according to their class and generic names.</p>
        <p>People exposed to HIV-positive infectious bodily fluids, either by skin puncture, damaged skin, or direct mucous membrane contact, are at risk for transmission. They should start antiretroviral therapy as soon as possible. The United States Public Health Service guidelines recommend starting prophylactics up to 72 hours postexposure. The recommended regimen is emtricitabine plus tenofovir plus raltegravir for&#x000a0;4 weeks. Those exposed to HIV should have follow-up HIV testing at 6, 12, and 24 weeks. If&#x000a0;the test results are negative at 24 weeks, they are considered uninfectious.<xref ref-type="bibr" rid="article-22917.r1">[1]</xref>&#x000a0;&#x000a0;In 2019, the FDA approved tenofovir alafenamide/emtricitabine as pre-exposure prophylaxis for adolescents and adults weighing at least 77&#x000a0;pounds (35 kg).<xref ref-type="bibr" rid="article-22917.r2">[2]</xref></p>
        <p>A Recent HIV infection is considered the phase of 6 months or less after infection.<xref ref-type="bibr" rid="article-22917.r3">[3]</xref> An HIV regimen often varies based on potential drug interactions&#x000a0;with the patient's current&#x000a0;medications and the adverse effects experienced. Pregnant patients should begin treatment immediately to prevent mother-to-child transmission of HIV and protect the woman's health.<xref ref-type="bibr" rid="article-22917.r4">[4]</xref><xref ref-type="bibr" rid="article-22917.r5">[5]</xref></p>
        <p>The following includes all FDA-approved HIV medications:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>NRTIs:</bold> Abacavir, emtricitabine, lamivudine; tenofovir&#x000a0;disoproxil&#x000a0;fumarate, zidovudine</p>
          </list-item>
          <list-item>
            <p><bold>NNRTIs:</bold> Efavirenz, etravirine, nevirapine, rilpivirine</p>
          </list-item>
          <list-item>
            <p><bold>Fusion inhibitors (FIs):</bold> Enfuvirtide</p>
          </list-item>
          <list-item>
            <p><bold>Protease inhibitors (PIs):</bold> Atazanavir, darunavir, fosamprenavir, ritonavir, saquinavir, tipranavir</p>
          </list-item>
          <list-item>
            <p><bold>Chemokine receptor 5 (CCR5) antagonist:</bold> Maraviroc</p>
          </list-item>
          <list-item>
            <p><bold>IIs:</bold>&#x000a0;Dolutegavir, raltegravir,&#x000a0;elvitegravir, bictegravir</p>
          </list-item>
          <list-item>
            <p><bold>Postattachment inhibitors:</bold> Ibalizumab</p>
          </list-item>
          <list-item>
            <p><bold>Pharmacokinetic Enhancers:</bold> Cobicistat</p>
          </list-item>
        </list>
        <p>The following includes all FDA-approved HIV combination medicines:</p>
        <list list-type="bullet">
          <list-item>
            <p>Abacavir and lamivudine</p>
          </list-item>
          <list-item>
            <p>Abacavir,&#x000a0;dolutegravir, and lamivudine</p>
          </list-item>
          <list-item>
            <p>Abacavir, lamivudine, and zidovudine</p>
          </list-item>
          <list-item>
            <p>Atazanavir and cobicistat</p>
          </list-item>
          <list-item>
            <p>Bictegravir, emtricitabine, and tenofovir&#x000a0;alafenamide (TAF)</p>
          </list-item>
          <list-item>
            <p>Darunavir and cobicistat</p>
          </list-item>
          <list-item>
            <p>Dolutegravir&#x000a0;and rilpivirine</p>
          </list-item>
          <list-item>
            <p>Efavirenz, emtricitabine, and tenofovir&#x000a0;disoproxil&#x000a0;fumarate (TDF)</p>
          </list-item>
          <list-item>
            <p>Efavirenz, lamivudine, and&#x000a0;TDF</p>
          </list-item>
          <list-item>
            <p>Efavirenz, lamivudine, and&#x000a0;TDF</p>
          </list-item>
          <list-item>
            <p>Elvitegravir, cobicistat, emtricitabine, and&#x000a0;TAF</p>
          </list-item>
          <list-item>
            <p>Elvitegravir, cobicistat, emtricitabine, and&#x000a0;TDF</p>
          </list-item>
          <list-item>
            <p>Emtricitabine, rilpivirine, and&#x000a0;TAF</p>
          </list-item>
          <list-item>
            <p>Emtricitabine, rilpivirine, and tenofovir&#x000a0;disoproxil&#x000a0;fumarate (TDF)</p>
          </list-item>
          <list-item>
            <p>Emtricitabine and&#x000a0;TAF</p>
          </list-item>
          <list-item>
            <p>Emtricitabine and&#x000a0;TDF</p>
          </list-item>
          <list-item>
            <p>Lamivudine and&#x000a0;TDF</p>
          </list-item>
          <list-item>
            <p>Lamivudine and zidovudine</p>
          </list-item>
          <list-item>
            <p>Lopinavir and ritonavir</p>
          </list-item>
        </list>
        <p>The FDA does not approve investigational HIV drugs. Investigational drugs include those used to treat or prevent HIV and vaccines to treat or prevent HIV. These drugs are only available in clinical trials. No vaccines exist yet; however, researchers are studying this possibility.<xref ref-type="bibr" rid="article-22917.r6">[6]</xref></p>
        <p>The following are recommended starting regimens for the majority of patients with HIV-1 (treatment-naive patients):</p>
        <list list-type="bullet">
          <list-item>
            <p>Bictegravir, tenofovir alafenamide, and emtricitabine</p>
          </list-item>
          <list-item>
            <p>Dolutegravir (emtricitabine or lamivudine)&#x000a0;and&#x000a0;TAF (or TDF)&#x000a0;<xref ref-type="bibr" rid="article-22917.r7">[7]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22917.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>
<bold>NRTIs</bold>
</p>
        <p>NRTIs compete with natural deoxynucleotides for incorporation into a growing viral DNA chain. However, NRTIs lack a 3'-hydroxyl group on the deoxyribose moiety. This difference results in incorporating an NRTI, and the next incoming deoxynucleotide cannot form the following 5', 3' phosphodiester bond needed to extend the DNA chain. The result is a chain termination in DNA synthesis.</p>
        <p>
<bold>NNRTIs</bold>
</p>
        <p>NNRTIs block reverse transcriptase (RT) by directly binding to the enzyme. Though NNRTIs do not get incorporated into the viral DNA, they inhibit the movement of protein domains of RT that are essential to carrying out the DNA synthesis.</p>
        <p>
<bold>Protease Inhibitors</bold>
</p>
        <p>Protease inhibitors bind HIV-1 protease and block proteolytic cleavage of protein precursors necessary for producing viral particles.</p>
        <p>
<bold>Fusion Inhibitors</bold>
</p>
        <p>Fusion inhibitors disrupt binding, fusion, and entry of HIV virions into a human cell. Enfuvirtide binds to gp41 and disrupts membrane attachment.</p>
        <p>
<bold>CCR5 Antagonist</bold>
</p>
        <p>Maraviroc blocks the CCCR receptor on the T-cell to prevent viral attachment.</p>
        <p>
<bold>Integrase Inhibitors</bold>
</p>
        <p>Integrase inhibitors block the action of integrase, preventing the viral genome from inserting itself into the DNA of a host cell.</p>
        <p>
<bold>Postattachment Inhibitors</bold>
</p>
        <p>This class is a monoclonal antibody that binds CD4, inhibiting viral entry into the cell.</p>
        <p>
<bold>Pharmacokinetic Enhancers</bold>
</p>
        <p>Pharmacokinetic enhancers inhibit human CYP3A protein, increasing plasma concentration of other anti-HIV drugs.<xref ref-type="bibr" rid="article-22917.r8">[8]</xref></p>
      </sec>
      <sec id="article-22917.s4" sec-type="Administration">
        <title>Administration</title>
        <p>The standard of care in an HIV regimen is to prevent HIV mutation. As a patient will take these medications orally, there are now several options that combine three to four drugs into one pill for better patient compliance due to once-daily administration. This dosing increases both adherence and long-term effectiveness. Ibalizumab is an exception, as it is an injectable agent.<xref ref-type="bibr" rid="article-22917.r9">[9]</xref></p>
        <p>Patients are tested and educated to take all of their medications correctly to reduce resistance and cross-resistance&#x000a0;to similar drugs to those they are taking. Medication adherence is difficult&#x000a0;due to adverse effects following an HIV regimen. Common barriers to adherence include trouble swallowing pills, a busy schedule (shift work), unstable living or housing situations, alcohol&#x000a0;or drug use, fear of disclosing&#x000a0;HIV status, and lack of insurance. Before starting an HIV regimen, strategies such as 7-day pillboxes, phone applications, and alarms should be in place. Patients must have stable mental health and&#x000a0;not be taking illicit drugs to have better adherence.<xref ref-type="bibr" rid="article-22917.r10">[10]</xref><xref ref-type="bibr" rid="article-22917.r11">[11]</xref></p>
        <p>
<bold>Use in Specific Patient Populations</bold>
</p>
        <p>
<bold>Hepatic impairment</bold>
</p>
        <p>Guidance for treating HIV in patients with hepatic impairment&#x000a0;is as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>In patients with moderate or severe hepatic impairment:</bold>&#x000a0;Regimens that are not recommended&#x000a0;include&#x000a0;efavirenz/TDF and TDF/lamivudine.<xref ref-type="bibr" rid="article-22917.r12">[12]</xref><xref ref-type="bibr" rid="article-22917.r13">[13]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>In patients with&#x000a0;Child-Pugh Class B or C:</bold><italic toggle="yes">&#x000a0;</italic>Abacavir, abacavir/lamivudine,&#x000a0;and dolutegravir/abacavir/lamivudine&#x000a0;are not recommended due to the abacavir component; nevirapine is contraindicated; and the use of&#x000a0;TAF is not recommended.<xref ref-type="bibr" rid="article-22917.r14">[14]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>General guidance:</bold>&#x000a0;Abacavir and nevirapine are contraindicated in patients with hepatic impairment.</p>
          </list-item>
        </list>
        <p>
<bold>Renal impairment</bold>
</p>
        <p>Caution should be exercised if the patient is on a tenofovir-containing regimen due to potential nephrotoxicity. The CDC's recommendations are as follows:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Creatinine clearance (CrCl) less than 30 mL/min:</bold> Elvitegravir, cobicistat,&#x000a0;TDF, and&#x000a0;emtricitabine should not be initiated.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Regimens not recommended:</bold>&#x000a0;Efavirenz, TDF/emtricitabine, doravirine/TDF/lamivudine, efavirenz/TDF/lamivudine, and rilpivirine/TDF/emtricitabine</p>
          </list-item>
          <list-item>
            <p><bold>Recommended regimens:</bold> Use the individual component antiretrovirals (ARVs) and modify doses according to creatinine clearance.</p>
          </list-item>
          <list-item>
            <p><bold>General guidance:&#x000a0;</bold>Avoid any combination containing tenofovir due to the risk of potential nephrotoxicity; dolutegravir/lamivudine, abacavir/lamivudine, and dolutegravir/ abacavir/lamivudine&#x000a0;are not recommended.&#x000a0;</p>
          </list-item>
        </list>
        <p>For patients on hemodialysis whose CrCl is less than 30 mL/min, the recommendations are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>TAF/emtricitabine:</bold>&#x000a0;One tablet once daily. On&#x000a0;hemodialysis days, administer after dialysis.</p>
          </list-item>
          <list-item>
            <p><bold>Bictegravir/TAF/emtricitabine:</bold> One tablet once daily. On&#x000a0;hemodialysis days, administer after dialysis.</p>
          </list-item>
          <list-item>
            <p><bold>Elvitegravir/cobicistat/TAF/emtricitabine:</bold> One tablet once daily. On&#x000a0;hemodialysis days, administer after dialysis.</p>
          </list-item>
          <list-item>
            <p><bold>Rilpivirine/TAF/emtricitabine:</bold> One tablet once daily. On&#x000a0;hemodialysis days, administer after dialysis.</p>
          </list-item>
          <list-item>
            <p><bold>Darunavir/cobicistat/TAF/emtricitabine:</bold> One tablet once daily. On&#x000a0;hemodialysis days, administer after dialysis.<xref ref-type="bibr" rid="article-22917.r14">[14]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Pregnancy considerations</bold>
</p>
        <p>The preferred regimen is integrase strand transfer inhibitor&#x000a0;(INSTI)-based therapy such as dolutegravir, emtricitabine, and tenofovir.<xref ref-type="bibr" rid="article-22917.r15">[15]</xref>&#x000a0;The dolutegravir, emtricitabine, and&#x000a0;TAF had the lowest frequency of composite adverse pregnancy outcomes and neonatal deaths.<xref ref-type="bibr" rid="article-22917.r16">[16]</xref>&#x000a0;According to CDC guidelines,&#x000a0;COVID-19 vaccination is strongly recommended for all pregnant patients with HIV infection.<xref ref-type="bibr" rid="article-22917.r17">[17]</xref></p>
        <p>
<bold>Breastfeeding considerations</bold>
</p>
        <p>Breastfeeding&#x000a0;is not recommended&#x000a0;for&#x000a0;patients who are confirmed or presumed to have HIV&#x000a0;infection. Infants exposed perinatally to HIV should receive postpartum ARV prophylaxis to&#x000a0;decrease the risk of perinatal transmission. The patient should be counseled that maternal antiretroviral therapy reduces but does not eliminate the risk of HIV transmission&#x000a0;to the infant. Hence, mothers should use safe and affordable infant feeding alternatives.<xref ref-type="bibr" rid="article-22917.r18">[18]</xref>&#x000a0;Four-week zidovudine antiretroviral prophylaxis is frequently used in newborns whose mothers received ART during pregnancy and had&#x000a0;adequate viral suppression four weeks before delivery. Higher rates of hematologic toxicity have been observed in infants who received zidovudine (ZDV) plus lamivudine (3TC) and other combination infant ARV regimens&#x000a0;(such as ZDV plus 3TC plus nevirapine [NVP]) than in those who received ZDV alone.<xref ref-type="bibr" rid="article-22917.r19">[19]</xref>&#x000a0;</p>
        <p>Another study combined zidovudine/lamivudine/NVP prophylaxis for neonates with&#x000a0;high-risk&#x000a0;infants and did not significantly increase the risk of short-term toxicity compared with ZDV-monotherapy.<xref ref-type="bibr" rid="article-22917.r20">[20]</xref>&#x000a0;Prevention of&#x000a0;<italic toggle="yes">Pneumocystis jirovecii</italic>&#x000a0;pneumonia requires&#x000a0;prophylaxis with trimethoprim-sulfamethoxazole&#x000a0;for infants delivered to mothers with HIV.<xref ref-type="bibr" rid="article-22917.r21">[21]</xref></p>
      </sec>
      <sec id="article-22917.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The following adverse effects&#x000a0;have been associated with&#x000a0;HIV medications:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>NRTIs:&#x000a0;</bold>Hypersensitivity reaction or rash, neutropenia, myopathy, anemia, neuropathy, mitochondrial toxicity, lactic acid build-up, pancreatitis, fever, rash, nausea, vomiting, diarrhea, abdominal pain, fatigue, achiness, shortness of breath, sore throat, dark-colored urine, lipoatrophy,&#x000a0;and jaundice&#x000a0;<xref ref-type="bibr" rid="article-22917.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p><bold>NNRTIs:&#x000a0;</bold>Severe rash, allergic reactions, depression, impaired concentration, headache, sleep disturbance, abnormal dreams, mood changes, jaundice, dark-colored urine, fatigue, nausea and vomiting, peripheral neuropathy, mouth sores, conjunctivitis, myopathy, blisters, and trouble breathing</p>
          </list-item>
          <list-item>
            <p><bold>Protease inhibitors:&#x000a0;</bold>Irregular heart rhythm, lipodystrophy,&#x000a0;severe rash, jaundice, dizziness, lightheadedness, heartburn, fatigue, myopathy, conjunctivitis, mouth sores, mouth numbness, kidney stones, blisters, dark-colored urine, pancreatitis, painful swelling, and abdominal pain</p>
          </list-item>
          <list-item>
            <p><bold>Fusion inhibitors:&#x000a0;</bold>Injection site reactions, infection, trouble breathing, fever, blood in urine, dark-colored urine, low blood pressure, neutropenia, chills and shivering, and cough</p>
          </list-item>
          <list-item>
            <p><bold>CCR5 antagonists:&#x000a0;</bold>Allergic reaction, jaundice, dark-colored urine, vomiting, abdominal pain, fever, fatigue, myopathy, mouth and skin blisters, facial swelling, trouble breathing, upper respiratory tract infections, cough, joint pain, myopathy, pain below ribs, heart problems, and loss of appetite</p>
          </list-item>
          <list-item>
            <p><bold>Integrase inhibitors:&#x000a0;</bold>Allergic hypersensitivity reaction, rash, jaundice, dark-colored urine, pale bowel movements, diarrhea, flatulence, nausea and vomiting, loss of appetite, abnormal dreams, pruritus, pain below ribs, mouth and skin blisters, and fatigue</p>
          </list-item>
          <list-item>
            <p><bold>Postattachment inhibitors:&#x000a0;</bold>Immune reconstitution inflammatory syndrome</p>
          </list-item>
          <list-item>
            <p><bold>Pharmacokinetic enhancers:&#x000a0;</bold>Increased serum creatinine, proteinuria, nausea, diarrhea, headache, acute kidney injury, and kidney failure</p>
          </list-item>
        </list>
        <p>Some long-term adverse effects of HIV medicines are hepatotoxicity, kidney failure, heart disease, diabetes/insulin resistance, hyperlipidemia, osteoporosis, suicidal ideation&#x000a0;or depression, and nervous system deficits.<xref ref-type="bibr" rid="article-22917.r23">[23]</xref><xref ref-type="bibr" rid="article-22917.r24">[24]</xref></p>
      </sec>
      <sec id="article-22917.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The following contraindications are associated with HIV medications:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Abacavir:</bold> Patients with the HLA-B*5701 allele or prior hypersensitivity reaction to abacavir or moderate or severe hepatic impairment&#x000a0;<xref ref-type="bibr" rid="article-22917.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Emtricitabine:</bold> Patients with previously demonstrated hypersensitivity to any of the components of the products</p>
          </list-item>
          <list-item>
            <p><bold>Lamivudine:</bold> Patients with a previous hypersensitivity reaction to lamivudine</p>
          </list-item>
          <list-item>
            <p><bold>TDF:</bold> Previous hypersensitivity or glomerular filtration rate less than 50</p>
          </list-item>
          <list-item>
            <p><bold>Zidovudine:</bold> Patients who have had potentially life-threatening allergic reactions (eg, anaphylaxis, Stevens-Johnson syndrome) to any of the components of the formulations</p>
          </list-item>
          <list-item>
            <p><bold>Efavirenz:</bold> Patients with clinically significant hypersensitivity&#x000a0;(eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the ingredients of this product; coadministration of efavirenz with elbasvir and grazoprevir is contraindicated.</p>
          </list-item>
          <list-item>
            <p><bold>Etravirine: </bold>Hypersensitivity</p>
          </list-item>
          <list-item>
            <p><bold>NVP:</bold>&#x000a0;In patients with moderate or severe (Child-Pugh Class B or C, respectively) hepatic impairment or for use as occupational and nonoccupational postexposure prophylaxis regimens. Women with CD4 greater than 250 or men with CD4 greater than 400 due to an increased probability of hypersensitivity reaction. Hepatotoxicity is largely cholestatic but demonstrates hepatocellular pattern as well. In some&#x000a0;cases, reports of clinically apparent hepatotoxicity are present after the first eight weeks of therapy but can be severe and fatal.<xref ref-type="bibr" rid="article-22917.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Rilpivirine:</bold> Contraindicated for coadministration with all of the following: carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifapentine, dexamethasone, St. John&#x02019;s wort, esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole</p>
          </list-item>
          <list-item>
            <p><bold>Atazanavir:</bold> In patients with previously demonstrated clinically significant hypersensitivity&#x000a0;(eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the formulation ingredients; concurrent administration&#x000a0;of&#x000a0;medications that are highly dependent on cytochrome P450 3A4 (CYP3A) or UDP Glucuronosyl transferase Family 1 Member A1&#x000a0;(UGT1A1) for clearance is associated with elevated plasma concentrations of the interacting drugs and severe life-threatening events&#x000a0;(when coadministered with drugs that strongly induce CYP3A4,&#x000a0;atazanavir&#x000a0;may lead to lower exposure and loss of formulations' efficacy).</p>
          </list-item>
          <list-item>
            <p><bold>Darunavir:</bold> Coadministration of formulations is contraindicated with medications highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and life-threatening events.</p>
          </list-item>
          <list-item>
            <p><bold>Fosamprenavir:</bold> In patients with previously demonstrated clinically significant hypersensitivity&#x000a0;(eg, Stevens-Johnson syndrome), to any of the components of this product or amprenavir; when coadministered with medications that are highly dependent on CYP3A4 for clearance and for which elevated plasma concentrations are associated with serious and life-threatening events.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Ritonavir:</bold> Contraindicated in patients with known hypersensitivity, for example, toxic epidermal necrolysis or Stevens-Johnson syndrome, to ritonavir or any of its ingredients. Ritonavir is contraindicated with medications highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and life-threatening reactions. It is also contraindicated with drugs that are potent CYP3A inducers, where significantly reduced lopinavir plasma concentrations may correlate with the potential for loss of virologic response and possible resistance and cross-resistance.<xref ref-type="bibr" rid="article-22917.r27">[27]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Saquinavir:</bold> Contraindicated in those with congenital long QT syndrome, those with refractory hypokalemia or hypomagnesemia, and with concurrent administration with drugs that increase saquinavir plasma concentrations and prolong the QT interval. It is also contraindicated in people with complete atrioventricular block without implanted pacemakers or patients at high risk of complete atrioventricular block. In addition, it is contraindicated in patients with clinically significant hypersensitivity (eg, anaphylactic reaction, Stevens-Johnson syndrome) to saquinavir, saquinavir mesylate, or any of its ingredients; in patients with severe hepatic impairment. It is also contraindicated with drugs that are CYP3A substrates, for which increased plasma levels may result in serious or life-threatening reactions.</p>
          </list-item>
          <list-item>
            <p><bold>Tipranavir:</bold> Use of tipranavir is contraindicated with concurrent administration of drugs highly dependent on CYP3A4 for clearance or potent CYP3A4 inducers due to increased risk of intracranial bleeding. Tipranavir is also contradicted in moderate to severe hepatic impairment.<xref ref-type="bibr" rid="article-22917.r28">[28]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Enfuvirtide:</bold> Known hypersensitivity to enfuvirtide or any of its components</p>
          </list-item>
          <list-item>
            <p><bold>Maraviroc:</bold> This drug is contraindicated in patients with severe renal impairment or&#x000a0;end-stage renal disease (CrCl &#x0003c;30 mL per minute) who concomitantly take potent CYP3A inhibitors or inducers.</p>
          </list-item>
          <list-item>
            <p><bold>Dolutegravir:</bold> Previous hypersensitivity reaction to dolutegravir or receiving dofetilide due to the potential for higher dofetilide plasma concentrations and the risk for severe and life-threatening events</p>
          </list-item>
          <list-item>
            <p><bold>Raltegravir:</bold> None</p>
          </list-item>
          <list-item>
            <p><bold>Ibalizumab:</bold> None</p>
          </list-item>
          <list-item>
            <p><bold>Cobicistat:</bold> The concomitant use of cobicistat with atazanavir is contraindicated&#x000a0;with drugs dependent on CYP3A or UGT1A1 for clearance and for which elevated plasma concentrations of the interacting drugs are&#x000a0;due to&#x000a0;serious life-threatening events. Darunavir and cobicistat should not be coadministered with drugs&#x000a0;highly dependent on CYP3A for clearance, which may lead to increased plasma concentrations&#x000a0;and life-threatening events.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22917.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The following tests should be performed to monitor patients on HIV antiretroviral therapy:</p>
        <p>
<bold>Initial Assessment&#x000a0;(Start of T</bold>
<bold>herapy)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>CD4 count</p>
          </list-item>
          <list-item>
            <p>HIV viral load</p>
          </list-item>
          <list-item>
            <p>Resistance testing</p>
          </list-item>
          <list-item>
            <p>HLA-B 5701 testing</p>
          </list-item>
          <list-item>
            <p>Tropism testing</p>
          </list-item>
          <list-item>
            <p>Hepatitis B serology</p>
          </list-item>
          <list-item>
            <p>Hepatitis C screening</p>
          </list-item>
          <list-item>
            <p>Complete blood count (CBC) with differential</p>
          </list-item>
          <list-item>
            <p>Basic chemistry&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Alanine transaminase (ALT), aspartate transaminase (AST), bilirubin</p>
          </list-item>
          <list-item>
            <p>Fasting lipid profile</p>
          </list-item>
          <list-item>
            <p>Fasting glucose and hemoglobin A1C</p>
          </list-item>
          <list-item>
            <p>Urinalysis</p>
          </list-item>
          <list-item>
            <p>Pregnancy test&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Every 3 to 6 Months</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>CD4 count for the first&#x000a0;2 years of antiretroviral therapy or if viremia develops</p>
          </list-item>
          <list-item>
            <p>HIV viral load</p>
          </list-item>
          <list-item>
            <p>Basic chemistry</p>
          </list-item>
          <list-item>
            <p>ALT, AST,&#x000a0; bilirubin</p>
          </list-item>
          <list-item>
            <p>CBC with differential if on zidovudine</p>
          </list-item>
          <list-item>
            <p>Fasting glucose and hemoglobin A1C if abnormal before</p>
          </list-item>
        </list>
        <p>
<bold>Every&#x000a0;6 Months</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>CBC with differential</p>
          </list-item>
          <list-item>
            <p>Urinalysis if on bictegravir/emtricitabine/TAF) or efavirenz/emtricitabine/TDF</p>
          </list-item>
        </list>
        <p>
<bold>Every 12 Months</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>After&#x000a0;2 years, if the CD4 count is 300 to 500, then every 12 months; if CD4 is greater than 500, monitoring is optional.</p>
          </list-item>
          <list-item>
            <p>Hepatitis B serology may be repeated unless the patient is immunized.</p>
          </list-item>
          <list-item>
            <p>Screen for hepatitis C if the patient is at risk.</p>
          </list-item>
          <list-item>
            <p>Fasting lipid profile</p>
          </list-item>
          <list-item>
            <p>Fasting glucose and hemoglobin A1C</p>
          </list-item>
          <list-item>
            <p>Urinalysis</p>
          </list-item>
          <list-item>
            <p>Quantiferon tuberculosis test</p>
          </list-item>
        </list>
        <p>
<bold>Treatment Failure&#x000a0;or Modification</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>CD4 count</p>
          </list-item>
          <list-item>
            <p>HIV viral load</p>
          </list-item>
          <list-item>
            <p>Resistance testing</p>
          </list-item>
          <list-item>
            <p>Hepatitis B serology</p>
          </list-item>
          <list-item>
            <p>Hepatitis C screening</p>
          </list-item>
          <list-item>
            <p>Basic chemistry</p>
          </list-item>
          <list-item>
            <p>ALT/AST/bilirubin</p>
          </list-item>
          <list-item>
            <p>CBC with differential</p>
          </list-item>
          <list-item>
            <p>Fasting lipid profile</p>
          </list-item>
          <list-item>
            <p>Fasting glucose and hemoglobin A1C</p>
          </list-item>
          <list-item>
            <p>Urinalysis</p>
          </list-item>
          <list-item>
            <p>Pregnancy test</p>
          </list-item>
          <list-item>
            <p>Tropism testing<xref ref-type="bibr" rid="article-22917.r29">[29]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22917.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Many HIV medicines have adverse effects that may require supportive treatment, monitoring, and adjustment of the HIV regimen.<xref ref-type="bibr" rid="article-22917.r23">[23]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>NVP:</bold> Therapy with&#x000a0;NVP is associated with significant transaminase elevations in 4% to 20% of patients and symptomatic elevations in 1% to 5% of patients. Among the more than 20 antiretroviral agents, NVP is perhaps the most common cause of serious, clinically apparent acute liver injury. The clinically apparent liver injury due to nevirapine is as high as 1%, with fatalities ensuing in approximately 0.1% of treated patients. The onset of injury is within the first 6 to 8 weeks of therapy. The presenting symptoms are typically abdominal pain and fatigue, followed by fever, rash, and jaundice. Most patients have a cholestatic hepatic injury pattern, but hepatocellular injury is also observed in severe cases. NVP&#x000a0;hepatotoxicity can be severe and fatal, and cases requiring emergency liver transplantation have been described.&#x000a0;NVP should be promptly discontinued if serum aminotransferase levels rise about&#x000a0;10 times the upper limit of normal, persistently above&#x000a0;5 times above the upper limit of normal, or if associated with bilirubin elevations or hepatitis.<xref ref-type="bibr" rid="article-22917.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Tenofovir:</bold> Long-term tenofovir is associated with nephrotoxicity and Fanconi syndrome and should be avoided in patients with preexisting renal impairment.</p>
          </list-item>
          <list-item>
            <p><bold>Zidovudine:</bold> Zidovudine-associated myelosuppression manifests with neutropenia and anemia, and its overdose has been described in neonates receiving HIV prophylaxis.</p>
          </list-item>
          <list-item>
            <p><bold>Efavirenz:</bold> Overdoses of efavirenz present with neuropsychiatric manifestations.</p>
          </list-item>
          <list-item>
            <p><bold>Protease inhibitors:</bold>&#x000a0;These have been associated with insulin resistance, type II diabetes mellitus, and lipodystrophy.</p>
          </list-item>
          <list-item>
            <p><bold>NRTIs:</bold>&#x000a0;Mitochondrial toxicity associated with using NRTIs leads to myopathy, liver failure, and lactic acidosis. Lactic acidosis is fatal if not recognized. In patients with lactic acidosis, NRTIs must be immediately stopped, and clinicians&#x000a0;should immediately administer&#x000a0;supportive care.<xref ref-type="bibr" rid="article-22917.r30">[30]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22917.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of patients with HIV is best with an interprofessional team that includes&#x000a0;doctors,&#x000a0;nurse practitioners, physician assistants, infectious specialists, pharmacists (including infectious disease specialty pharmacists who focus on antiretroviral treatment), and infectious disease nurses. The pharmacist should verify the chosen regimen, check for drug interactions, verify dosing, and assume responsibility for patient counseling. Nursing can initially assess treatment effectiveness and, particularly, patient compliance. They also must participate in patient education because improper compliance can lead to disastrous therapeutic failure. All healthcare team members must press the point of compliance when they have the opportunity, and any concerns about the regimen or compliance require communication with the treating physician. All interprofessional team members bear responsibility for patient monitoring, especially for compliance, and must record any concerns in the patient's medical record and reach out to the appropriate team member(s) immediately to take corrective action; this open communication is crucial to the success of HAART.</p>
        <p>Overwhelming data show that HAART can improve survival and reduce the risk of opportunistic infections. Thus, healthcare workers need to understand these medications because of their effectiveness and the potential adverse effects. A consultation with an infectious disease expert is recommended when&#x000a0;any doubts exist regarding&#x000a0;HAART.&#x000a0;Infectious disease clinicians and other healthcare professionals ensure adults and children with HIV receive safe and effective therapy.&#x000a0;Infectious specialists and healthcare professionals&#x000a0;are integral to formulating&#x000a0;domestic and global infectious disease policies to improve&#x000a0;public health.<xref ref-type="bibr" rid="article-22917.r31">[31]</xref> Poor retention in HIV care is associated with higher morbidity and mortality and a greater risk of HIV transmission. The Patient-Centered HIV Care Model incorporates community-based pharmacists with clinicians. PCHCM displayed that close collaborations between pharmacists and clinicians can improve the retention of patients with HIV, enhancing patient outcomes.<xref ref-type="bibr" rid="article-22917.r32">[32]</xref>&#x000a0;Only with a complete "all in," collaborative interprofessional team approach can ART have its best chance for therapeutic success while minimizing adverse events.&#x000a0;</p>
      </sec>
      <sec id="article-22917.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22917&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22917">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22917/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22917">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22917.s11">
        <title>References</title>
        <ref id="article-22917.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riddell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Amico</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>HIV Preexposure Prophylaxis: A Review.</article-title>
            <source>JAMA</source>
            <year>2018</year>
            <month>Mar</month>
            <day>27</day>
            <volume>319</volume>
            <issue>12</issue>
            <fpage>1261</fpage>
            <page-range>1261-1268</page-range>
            <pub-id pub-id-type="pmid">29584848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanner</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Miele</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Valentine</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Dunville</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kapogiannis</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents: Clinical Considerations, 2020.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2020</year>
            <month>Apr</month>
            <day>24</day>
            <volume>69</volume>
            <issue>3</issue>
            <fpage>1</fpage>
            <page-range>1-12</page-range>
            <pub-id pub-id-type="pmid">32324724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Cowan</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>McGowan</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Vail</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Merrick</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Radix</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <source>Diagnosis and Management of Acute HIV Infection [Internet]</source>
            <publisher-name>Johns Hopkins University</publisher-name>
            <publisher-loc>Baltimore (MD)</publisher-loc>
            <year>2021</year>
            <month>07</month>
            <pub-id pub-id-type="pmid">33074631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saleska</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Maierhofer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kwiek</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Use of Antiretroviral Therapy During Pregnancy and Adverse Birth Outcomes Among Women Living With HIV-1 in Low- and Middle-Income Countries: A Systematic Review.</article-title>
            <source>J Acquir Immune Defic Syndr</source>
            <year>2018</year>
            <month>Sep</month>
            <day>01</day>
            <volume>79</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-9</page-range>
            <pub-id pub-id-type="pmid">29847475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Donovan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Emeto</surname>
                <given-names>TI</given-names>
              </name>
            </person-group>
            <article-title>Mother-to-child transmission of HIV in Australia and other high-income countries: Trends in perinatal exposure, demography and uptake of prevention strategies.</article-title>
            <source>Aust N Z J Obstet Gynaecol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>58</volume>
            <issue>5</issue>
            <fpage>499</fpage>
            <page-range>499-505</page-range>
            <pub-id pub-id-type="pmid">29787622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trovato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D'Apice</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Prisco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Berardinis</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>HIV Vaccination: A Roadmap among Advancements and Concerns.</article-title>
            <source>Int J Mol Sci</source>
            <year>2018</year>
            <month>Apr</month>
            <day>19</day>
            <volume>19</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">29671786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dybul</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fauci</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Pau</surname>
                <given-names>AK</given-names>
              </name>
              <collab>Panel on Clinical Practices for the Treatment of HIV</collab>
            </person-group>
            <article-title>Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2002</year>
            <month>May</month>
            <day>17</day>
            <volume>51</volume>
            <issue>RR-7</issue>
            <fpage>1</fpage>
            <page-range>1-55</page-range>
            <pub-id pub-id-type="pmid">12027060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kausar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Said Khan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ishaq Mujeeb Ur Rehman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Akram</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Riaz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rasool</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hamid Khan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saleem</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Shamim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Malik</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A review: Mechanism of action of antiviral drugs.</article-title>
            <source>Int J Immunopathol Pharmacol</source>
            <year>2021</year>
            <season>Jan-Dec</season>
            <volume>35</volume>
            <fpage>20587384211002621</fpage>
            <pub-id pub-id-type="pmid">33726557</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bettiker</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Ibalizumab.</article-title>
            <source>Curr Opin HIV AIDS</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>354</fpage>
            <page-range>354-358</page-range>
            <pub-id pub-id-type="pmid">29746266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Endalamaw</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tezera</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Eshetie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ambachew</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Habtewold</surname>
                <given-names>TD</given-names>
              </name>
            </person-group>
            <article-title>Adherence to Highly Active Antiretroviral Therapy Among Children in Ethiopia: A Systematic Review and Meta-analysis.</article-title>
            <source>AIDS Behav</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>22</volume>
            <issue>8</issue>
            <fpage>2513</fpage>
            <page-range>2513-2523</page-range>
            <pub-id pub-id-type="pmid">29761291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Engler</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>L&#x000e8;n&#x000e0;rt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lessard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Toupin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lebouch&#x000e9;</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Barriers to antiretroviral therapy adherence in developed countries: a qualitative synthesis to develop a conceptual framework for a new patient-reported outcome measure.</article-title>
            <source>AIDS Care</source>
            <year>2018</year>
            <season>Jan-Dec</season>
            <volume>30</volume>
            <issue>sup1</issue>
            <fpage>17</fpage>
            <page-range>17-28</page-range>
            <pub-id pub-id-type="pmid">29719990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <chapter-title>Abacavir</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2016</year>
            <month>1</month>
            <day>4</day>
            <pub-id pub-id-type="pmid">31643550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <chapter-title>Lamivudine</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2019</year>
            <month>4</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">31643870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leowattana</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Antiviral Drugs and Acute Kidney Injury (AKI).</article-title>
            <source>Infect Disord Drug Targets</source>
            <year>2019</year>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>375</fpage>
            <page-range>375-382</page-range>
            <pub-id pub-id-type="pmid">31288730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lockman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brummel</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Ziemba</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Stranix-Chibanda</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Coletti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jean-Philippe</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Krotje</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fairlie</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Sax</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Moyo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chakhtoura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Stringer</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Masheto</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Korutaro</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cassim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mmbaga</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Jo&#x000e3;o</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hanley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Purdue</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Momper</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Thoofer</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Rooney</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Frenkel</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Amico</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Chinula</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Currier</surname>
                <given-names>J</given-names>
              </name>
              <collab>IMPAACT 2010/VESTED Study Team and Investigators</collab>
            </person-group>
            <article-title>Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.</article-title>
            <source>Lancet</source>
            <year>2021</year>
            <month>Apr</month>
            <day>03</day>
            <volume>397</volume>
            <issue>10281</issue>
            <fpage>1276</fpage>
            <page-range>1276-1292</page-range>
            <pub-id pub-id-type="pmid">33812487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilleece</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Krankowska</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>ART in pregnant women living with HIV.</article-title>
            <source>Lancet</source>
            <year>2021</year>
            <month>Apr</month>
            <day>03</day>
            <volume>397</volume>
            <issue>10281</issue>
            <fpage>1240</fpage>
            <page-range>1240-1241</page-range>
            <pub-id pub-id-type="pmid">33812476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ssentongo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Heilbrunn</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Ssentongo</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Advani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chinchilli</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Nunez</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis.</article-title>
            <source>Sci Rep</source>
            <year>2021</year>
            <month>Mar</month>
            <day>18</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>6283</fpage>
            <pub-id pub-id-type="pmid">33737527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levison</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cohan</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Breastfeeding and HIV-infected women in the United States: harm reduction counseling strategies.</article-title>
            <source>Clin Infect Dis</source>
            <year>2014</year>
            <month>Jul</month>
            <day>15</day>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>304</fpage>
            <page-range>304-9</page-range>
            <pub-id pub-id-type="pmid">24771330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nielsen-Saines</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Veloso</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Bryson</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Joao</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Pilotto</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Theron</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kreitchmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mussi-Pinhata</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Ceriotto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bethel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morgado</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Dickover</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Camarca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mirochnick</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Siberry</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Grinsztejn</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Moreira</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Bastos</surname>
                <given-names>FI</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moye</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mofenson</surname>
                <given-names>LM</given-names>
              </name>
              <collab>NICHD HPTN 040/PACTG 1043 Protocol Team</collab>
            </person-group>
            <article-title>Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>Jun</month>
            <day>21</day>
            <volume>366</volume>
            <issue>25</issue>
            <fpage>2368</fpage>
            <page-range>2368-79</page-range>
            <pub-id pub-id-type="pmid">22716975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anugulruengkitt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suntarattiwong</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ounchanum</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Srirompotong</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Jantarabenjakul</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sophonphan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Punnahitanon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pancharoen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cressey</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Chokephaibulkit</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Puthanakit</surname>
                <given-names>T</given-names>
              </name>
              <collab>CIPHER_AEPEP study team</collab>
            </person-group>
            <article-title>Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>38</volume>
            <issue>10</issue>
            <fpage>1045</fpage>
            <page-range>1045-1050</page-range>
            <pub-id pub-id-type="pmid">31365477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ewald</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Raatz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Boscacci</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Furrer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bucher</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Briel</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2015</year>
            <month>Apr</month>
            <day>02</day>
            <volume>2015</volume>
            <issue>4</issue>
            <fpage>CD006150</fpage>
            <pub-id pub-id-type="pmid">25835432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r22">
          <label>22</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Guzman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vijayan</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <chapter-title>HIV-Associated Lipodystrophy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>11</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">29630235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chawla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Patton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Punekar</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>de Ruiter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Steinhart</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population.</article-title>
            <source>Infect Dis Ther</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>183</fpage>
            <page-range>183-195</page-range>
            <pub-id pub-id-type="pmid">29761330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zanetti</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Roever</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gon&#x000e7;alves</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Resende</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update.</article-title>
            <source>Curr Atheroscler Rep</source>
            <year>2018</year>
            <month>Feb</month>
            <day>08</day>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>9</fpage>
            <pub-id pub-id-type="pmid">29423787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r25">
          <label>25</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Dean</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <chapter-title>Abacavir Therapy and <italic>HLA-B*57:01</italic> Genotype</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Pratt</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Pirmohamed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esquivel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kattman</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Malheiro</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <source>Medical Genetics Summaries [Internet]</source>
            <publisher-name>National Center for Biotechnology Information (US)</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2015</year>
            <month>9</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">28520363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r26">
          <label>26</label>
          <element-citation publication-type="book">
            <chapter-title>Nevirapine</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>5</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">31644202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tarasova</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Poroikov</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>HIV Resistance Prediction to Reverse Transcriptase Inhibitors: Focus on Open Data.</article-title>
            <source>Molecules</source>
            <year>2018</year>
            <month>Apr</month>
            <day>19</day>
            <volume>23</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">29671808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r28">
          <label>28</label>
          <element-citation publication-type="book">
            <chapter-title>Tipranavir</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>9</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">31643708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Obermeier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Symons</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wensing</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>HIV population genotypic tropism testing and its clinical significance.</article-title>
            <source>Curr Opin HIV AIDS</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>470</fpage>
            <page-range>470-7</page-range>
            <pub-id pub-id-type="pmid">22832711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Margolis</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Heverling</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Stolbach</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A review of the toxicity of HIV medications.</article-title>
            <source>J Med Toxicol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>26</fpage>
            <page-range>26-39</page-range>
            <pub-id pub-id-type="pmid">23963694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brito</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Dugdale</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Collins-Ogle</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Snowden</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Infectious Diseases/Human Immunodeficiency Virus Physician Ambassadors: Advancing Policy to Improve Health.</article-title>
            <source>Clin Infect Dis</source>
            <year>2021</year>
            <month>Oct</month>
            <day>05</day>
            <volume>73</volume>
            <issue>7</issue>
            <fpage>e2243</fpage>
            <page-range>e2243-e2250</page-range>
            <pub-id pub-id-type="pmid">33035316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22917.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Byrd</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Hardnett</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Clay</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Delpino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hazen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shankle</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Camp</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weidle</surname>
                <given-names>PJ</given-names>
              </name>
              <collab>Patient-Centered HIV Care Model Team</collab>
            </person-group>
            <article-title>Retention in HIV Care Among Participants in the Patient-Centered HIV Care Model: A Collaboration Between Community-Based Pharmacists and Primary Medical Providers.</article-title>
            <source>AIDS Patient Care STDS</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>58</fpage>
            <page-range>58-66</page-range>
            <pub-id pub-id-type="pmid">30648888</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
